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ABSTRACT
Introduction: Sodium glucose cotransporter 2
(SGLT2) inhibitors are effective blood-glucose-lowering
medications with beneficial effects on body weight in
patients with type 2 diabetes mellitus (T2DM).
However, observed weight loss is less than that
predicted from quantified glycosuria, suggesting a
compensatory increase in energy intake or a decrease
in energy expenditure. Studies using dual-energy X-ray
absorptiometry (DEXA) have suggested most body
weight change is due to loss of adipose tissue, but
organ-specific changes in fat content (eg, liver, skeletal
muscle) have not been determined. In this randomised,
double-blind, placebo-controlled crossover study, we
aim to study the compensatory changes in energy
intake, eating behaviour and energy expenditure
accompanying use of the SGLT2 inhibitor,
dapagliflozin. Additionally, we aim to quantify changes
in fat distribution using MRI, in liver fat using proton
magnetic resonance spectroscopy (1H-MRS) and in
central nervous system (CNS) responses to food
images using blood oxygen level dependent (BOLD)
functional MRI (fMRI).
Methods and analysis: This outpatient study will
evaluate the effect of dapagliflozin (10 mg), compared
with placebo, on food intake and energy expenditure at
7 days and 12 weeks. 52 patients with T2DM will be
randomised to dapagliflozin or placebo for short-term
and long-term trial interventions in a within
participants, crossover design. The primary outcome is
the difference in energy intake during a test meal
between dapagliflozin and placebo. Intake data are
collected automatically using a customised programme
operating a universal eating monitor (UEM). Secondary
outcomes include (1) measures of appetite regulation
including rate of eating, satiety quotient, appetite
ratings (between and within meals), changes in CNS
responses to food images measured using BOLD-fMRI,
(2) measures of energy expenditure and (3) changes in
body composition including changes in liver fat and
abdominal visceral adipose tissue (VAT) and
subcutaneous adipose tissue (SAT).
Ethical approval: This study has been approved by
the North West Liverpool Central Research Ethics
Committee (14/NW/0340) and is conducted in
accordance with the Declaration of Helsinki and the
Good Clinical Practice (GCP).
Trial registration number: ISRCTN14818531.
EUDRACT number 2013-004264-60.
BACKGROUND AND RATIONALE
Type 2 diabetes mellitus (T2DM) is a dis-
order characterised by hyperglycaemia and
Strengths and limitations of this study
▪ This is the first study to address the discrepancy
between the estimated and actual weight loss as
a result of SGLT2 inhibition in a prospective
within participant study design incorporating
short-term and long-term effects.
▪ The study is designed to assess macrostructure
and microstructure of eating behaviour and the
use of imaging modalities provide a neuro-
physiological and mechanical correlate.
▪ The sample size is relatively small, although pro-
vides sufficient power to answer the primary
research question.
▪ The measurement of energy expenditure is per-
formed using indirect calorimetry as opposed to
the gold standard whole body calorimetry.
▪ There may be a carryover effect on body weight
and body composition changes since there is no
wash-out period between the long-term cross
over, but any effect of this on the primary
outcome (food intake) should be minimal.
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insulin resistance, which leads to the development of
microvascular and macrovascular complications. It is a
major global public health challenge; the prevalence is
expected to rise to 592 million by 2035.1 A range of
pharmacological therapies to complement lifestyle inter-
ventions with diet and exercise are available including
biguanides, sulphonylureas, thiazolidenediones,
glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl
peptidase-IV (DPP-IV) inhibitors, as well as insulin.
These therapies are usually unable to alter the natural
progression of T2DM. Obesity is a major risk factor for
T2DM, yet some treatments, particularly sulphonylureas,
thiazolidenediones and insulin, may cause weight gain.
Hence therapeutic agents that are weight neutral or
associated with weight loss may be preferable. Inhibition
of renal tubular reabsorption of glucose to induce glyco-
suria is effective in animal models2 and has led to the
development of sodium/glucose cotransporter 2
(SGLT2) inhibitors for clinical use.
SGLT2 inhibitors such as dapagliflozin have been
shown to cause significant reductions in glycaemia in
patients with T2DM, comparable with those produced
by other oral agents.3–6 In contrast to existing oral
agents, treatment results in weight loss in all groups
studied to date, including treatment-naive patients and
those where SGLT2 inhibitors were added to other oral
agents, insulin alone or a combination of oral agents
with insulin. SGLT2 inhibition results in a net loss of
∼75 g glucose per day, equivalent to an energy loss of
∼300 kcal/day (1200 kJ/day), and also a diuresis
(∼400 mL/day), resulting in a modest intravascular
volume depletion (evidenced by a rise in haematocrit).
The predicted weight loss over 24 weeks treatment with
dapagliflozin (assuming no compensatory changes in
either food intake or energy expenditure and no diur-
esis) based on the calculated caloric loss would be
∼7 kg. However, clinical data so far suggest that the
observed total weight loss with dapagliflozin 10 mg dose
is 2.5–3.2 kg (1.7–2.0 kg placebo-subtracted), that is, an
actual (placebo-subtracted) energy deficit of ∼320 kJ/
day, which is substantially less than the measured urinary
energy losses.
This suggests that with chronic treatment there are
compensatory mechanisms that attenuate weight loss.7
These could include either an increase in food intake,
driven by hunger (weakened satiety) and increased
responsiveness to food cues (reward driven wanting), or
a reduction in energy expenditure. As in human T2DM,
rats with dietary-induced obesity lose weight when
treated with dapagliflozin (∼4%), but this is offset by a
30% compensatory increase in energy intake.8
Furthermore, pair-feeding matched to vehicle-treated
animals leads to greater weight loss of ∼13%. In SGLT2
knockout mice, food intake was greater during the dark
cycle than controls; physical activity also increased,
energy expenditure was higher and respiratory quotient
(RQ) fell, consistent with a shift from carbohydrate to
fat metabolism. Human studies also demonstrate a shift
from glucose to fat metabolism.9 Overall these data are
consistent with the observations in humans and suggest
that some compensatory increase in food intake occurs
that limits the weight loss in dapagliflozin treatment; the
metabolic changes also suggest that fuel usage may shift
from carbohydrate to fat metabolism.10 Considering the
associated weight loss, improved glycaemia and prefer-
ence for fat metabolism, we believe that liver fat may
also be reduced, an effect observed with GLP-1 receptor
agonists.11
This study is designed to examine the behavioural and
biological mechanisms underlying the changes in energy
balance that occur with treatment with the SGLT2 inhibi-
tor, dapagliflozin, to evaluate changes in body compos-
ition and also to help answer important physiological
questions regarding adaptive responses to a state of nega-
tive energy balance mediated by promoting glycosuria.
PRIMARY OBJECTIVE
To evaluate the effect of dapagliflozin, 10 mg daily, com-
pared with placebo, when added to up to two other oral
glucose-lowering medications, on energy intake at a test
meal after 12 weeks of oral administration of treatment.
SECONDARY OBJECTIVES
To evaluate the changes in the following outcome mea-
sures with dapagliflozin, 10 mg daily, after 7 days and at
12 weeks, compared with placebo, when added to up to
two other oral glucose-lowering medications on:
1. Energy intake and appetite expression at a test meal
after 7 days (hunger and satiety).
2. Total energy expenditure and RQ derived from venti-
lated hood measurements after 7 days and after
12 weeks.
3. Changes in central nervous system (CNS) responses
to food images using blood oxygen level dependent
(BOLD) fMRI after 7 days and after 12 weeks (reward
driven eating).
4. Visceral and subcutaneous adipose tissue volumes
(VAT/SAT) using MRI after 12 weeks.
5. Liver fat, using proton magnetic resonance spectros-
copy (1H-MRS).
In addition, this study will address the effects of dapa-
gliflozin on the rate of eating and satiety quotient.
METHODS AND ANALYSIS
Overall design, investigational plan and study population
This will be an outpatient, double-blind, placebo-
controlled crossover study, to compare the effects of
dapagliflozin with placebo on food intake and energy
expenditure over periods of 7 days and 12 weeks.
Fifty-two participants with T2DM will be recruited: aged
18–75 years, with glycated haemoglobin (HbA1c) <11%
(97 mmol/mol) and either HbA1c ≥6.5% (48 mmol/
mol) in patients who are not on sulphonylureas (eg, gli-
clazide, glimepiride), or HbA1c ≥7.0% (53 mmol/mol)
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in patients who are on sulphonylureas. Each participant
will visit the study centre on 12 occasions: first, to under-
take routine screening tests. If identified as eligible, sub-
sequent visits involve consuming a test meal at baseline
or following placebo or dapagliflozin 10 mg, respectively,
and to undertake MR measurements. All patients will
receive 7 days of dapagliflozin or placebo followed by
12 weeks of each treatment. Each participant will serve
as their own control with the crossover between drug
and placebo at short-term and long-term. The 7-day
cross-over measurements will determine the short-term
effects of energy loss on food intake and energy expend-
iture (at this stage, it is unlikely that significant weight
loss would have occurred), while the long-term crossover
at 12 weeks investigates the compensatory changes at
dynamic stages of weight loss. The overall study design is
illustrated (figure 1), with the full crossover design
shown as study schematic (figure 2). Participants will be
randomised to one of the four treatment sequences
(figure 2).
The inclusion and exclusion criteria for the study are
summarised below.
Inclusion criteria
1. T2DM, either treated with diet alone or up to two
other oral agents (excluding pioglitazone) with an
HbA1c ≥6.5% (48 mmol/mol) in patients who are
not on sulphonylureas (eg, gliclazide, glimepiride)
and ≥7.0% (53 mmol/mol) in those patients who are
on sulphonylureas and <11% (97 mmol/mol).
2. BMI 20–50 kg/m2.
3. Men and women, age 18–75 years.
Exclusion criteria
1. Medical history and concurrent diseases
A. Type 1 diabetes mellitus.
B. History of diabetic ketoacidosis or hyperosmo-
lar non-ketotic coma.
C. Hyperthyroidism.
D. Hypothyroidism (although participants with a
normal TSH and free T4, and on a stable dose
of thyroxine for at least 3 months, may be
included).
E. Uncontrolled hypertension (blood pressure
>150/90 mm Hg).
F. Recent (<6 months) myocardial infarction.
G. Previous stroke.
H. Significant cardiac dysrhythmias (including
pacemaker or implantable cardiac defibrillator
device).
I. Known liver cirrhosis, viral hepatitis or auto-
immune liver disease.
J. Familial renal glycosuria.
K. History of seizures or unexplained syncope.
L. Pregnancy.
M. Recent major change in body weight (>3 kg
loss or gain in preceding month).
N. BMI <20 kg/m2.
O. History of malignancy.
P. Presence of any other medical condition that
would, in the opinion of the investigator, pre-
clude safe participation in the study.
Q. Alcohol consumption in excess of daily recom-
mended limits (14 units/week women,
21 units/week men).
R. Any history of internal metal, pacemakers or
ferromagnetic metallic implants intraocular
foreign bodies or cerebral aneurysm clips
(exclusion from MR scanning).
2. Physical and laboratory test findings
A. ALT>3×upper limit of normal (ULN).
B. AST>3×ULN.
C. Bilirubin>2×ULN.
D. Haemoglobin≤10.5 g/dL (≤105 g/L) for men;
haemoglobin≤9.5 g/dL (≤95 g/L) for women.
E. eGFR<60 mL/min.
F. Unexplained haematuria.
G. Weight>150 kg (due to limitations of MRI
scanner).
3. Allergies and adverse drug reactions
A. Any history of any serious hypersensitivity reac-
tion to dapagliflozin or SGLT-2 inhibitor.
B. Any allergy or intolerance to any of the study
foods.
4. Sex and reproductive status
A. WOCBP (woman of childbearing potential)
who are unwilling or unable to use an accept-
able method to avoid pregnancy for the study
duration plus 8 weeks.
B. Women who are pregnant or breastfeeding.
C. Sexually active fertile men not using effective
birth control if their partners are WOCBP.
5. Prohibited treatments and/or therapies
A. Diabetes treated with pioglitazone, GLP-1 ana-
logues or insulin.
B. Use of other weight loss medication or any
drug that might affect body weight or appetite
(including antidepressants, antipsychotics,
corticosteroids).
C. Patients who are already receiving dapagliflozin
or another SGLT inhibitor.
D. Patients who have participated in a SGLT2 clin-
ical trial within the past 30 days.
E. Patients who are currently receiving a loop
diuretic.
6. Other exclusion criteria
A. Prisoners or participants who are involuntarily
incarcerated.
B. Participants who are compulsorily detained for
treatment of either a psychiatric or physical
(eg, infectious disease) illness.
Outcome measures
The primary outcome is the change in energy intake at
12 weeks. Participants with T2DM who are recruited to
similar trials typically have a mean weight of 85–95 kg
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and are sedentary or minimally physically active with an
expected daily energy expenditure of 1780–2100 kcal.
The energy loss secondary to dapagliflozin treatment is
300 kcal/day, and the placebo-subtracted weight loss is
1.5–2 kg equivalent to ∼62–83 kcal/day. Thus, the
expected compensatory increase in energy intake is
∼220–240 kcal/day. Accounting for the osmotic diuresis
and 10% compensatory increase as a result of this, this
would further increase to ∼240–260 kcal/day (12.5–
13.4% of intake).
Sample size
The primary outcome measure is energy intake after
12 weeks. On the basis of previous research,12 we esti-
mate that 52 participants are required in order to detect
a change in energy intake of 12.5% with 80% power and
at a two-sided 5% level of significance. This estimate is
based on a correlation between measurements of 0.7
and a between-participant SD of 165, both of which are
based on a previous trial.12 The change in energy intake
of 12.5% is based on a baseline consumption of 460 g in
Figure 2 Study crossover schematic.
Figure 1 Study schematic.
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the test meal (ie, a 12.5% change equates to a change of
57.5 g). This calculation incorporates an allowance for
participant dropout of 20%. The estimate was calculated
using PROC POWER in SAS V.9.3 and is based on the
paired t-test.
The study is not formally powered to detect differ-
ences in liver or visceral fat, but in a previous study we
were able to detect a clear reduction or 7–11% of sub-
cutaneous and visceral adipose tissue and a reduction in
liver fat of 42% (IQR: −59.3 to −16.5%) with GLP-1 ana-
logue treatment on a study of n=25 in a pre-post treat-
ment analysis.11
Recruitment will take place over 12 months and will
take place in Aintree University Hospital, Liverpool, UK
(four to five patients per month). Participants will be
recruited either from existing databases of volunteer
patients, diabetes clinics in the hospital and community
and by advertisement in the local press. The randomisa-
tion for each stratum will be performed within balanced
blocks to ensure approximately equal numbers of parti-
cipants across the treatment sequences within each
stratum. The randomisation will be performed in two
strata, female and male participants.
Screening, enrolment and randomisation
After giving written informed consent, potentially eli-
gible participants will attend a screening visit within
6 weeks prior to randomisation; this includes a medical
history to confirm the participant’s eligibility to partici-
pate as determined by the inclusion/exclusion criteria,
physical examination, blood tests, urinalysis and an
ECG. A decision as to the participant’s eligibility will be
made once all the results are available. The number and
size of tablets will be identical for the investigational pro-
ducts (dapagliflozin 10 mg and placebo) for the four
treatment sequences.
Dosage and administration of study treatments
Participants will be instructed to take a tablet with water
(dapagliflozin 10 mg or matching placebo) each
morning for the duration of the study (26 weeks) while
continuing with their other usual medication and to
attend for scheduled study visits. Participants will be
asked to return all unused investigational products,
including any empty packages to the study pharmacy at
each visit. The participant’s compliance will be discussed
at each study visit and assessed based on returned tablet
counts.
Study visits and procedures
Test meal visits (visits 1, 3, 5, 9 and 13)
These will take place at baseline, after 7 days and
14 days, 14 weeks and 26 weeks of treatment (tables 1
and 2). On visit 1, participants will be asked to attend
the investigational unit at 8:00, having had nothing to
eat or drink other than water from midnight. To keep
study procedures identical for all test days, participants
will then be asked to take a dose of (single blind)
placebo tablet. Participants will be weighed and their
pulse and blood pressure recorded. An explanation and
demonstration of Visual Analogue Scale (VAS) question-
naires, universal eating monitor (UEM) and ventilated
hood will be given.
This procedure will be followed on additional test days
(visits 2, 6 and 10). Drug/placebo administration will
Table 1 Study procedures
Time point guidelines Procedure
Arrival 8:30 7 mL blood sample taken
(visit 9 only)
Placebo tablet taken
Weight, pulse and blood
pressure taken. Participants
asked to empty bladder and
start of timed urine collection
08:40 Basal metabolic rate
measurement (indirect
calorimetry—see below for
details)
08:50 Participants will complete a
series of pre-breakfast VAS
ratings to measure hunger
and other subjective
variables
09:00 Participants will be provided
with a fixed-quantity
breakfast, consisting of
cornflakes with milk, toast
and preserve, tea/coffee and
orange juice
10:00, 11:00, 12:00 (first
one followed by 3 every
hour)
Participants will complete the
same set of VAS ratings as
used pre-breakfast, providing
a premeal set of ratings
10:00 Indirect calorimetry
11:00 Indirect calorimetry
12:00 Indirect calorimetry
13:00 Participants will be given a
test meal in the UEM
laboratory. The meal consists
of a pasta dish with tomato
sauce, and participants may
eat ad lib and signal when
they have finished the meal.
The UEM will continuously
monitor decreases in food as
it is consumed and will
provide a continuous record
of food consumption
throughout the meal
14:00, 15:00, 16:00, 17:00
(1st one followed by 3
every hour)
Participants will complete the
same set of VAS ratings as
used pre-breakfast, providing
a postmeal set of ratings
14:00 Indirect calorimetry
15:00 Indirect calorimetry
16:00 Indirect calorimetry
UEM, universal eating monitor; VAS, Visual Analogue Scale.
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take place before the fixed breakfast is consumed on
each occasion.
Food intake and eating behaviour
Food intake and within meal assessment of hunger, full-
ness, desire to eat and prospective consumption will be
collected using the Sussex Ingestion Pattern Monitor
(SIPM V.2.0.13, University of Sussex), which comprises a
concealed digital balance linked to a computer system.
This system is similar to the UEM and allows continuous
recording of food intake throughout a meal as well as
custom programming for presentation of digital VASs
pre-meal and post-meal, and at set intervals during the
meal (every 150 g). Using this technology not only offers
accurate collection of cumulative intake data, but also
records data on subjective within meal measures of sati-
ation. The assessment of within meal measures of sati-
ation provides a behavioural correlate of satiety
processes during a meal.13 Thus, the mechanisms by
which potential increases in intake occur can be charac-
terised; for example, intake may be increased due to
weakened within meal satiation/delayed development of
satiety. Eating rate during the meal can also be assessed
using SIPM, as well as meal duration, satiety quotient
and ratings of palatability, providing essential informa-
tion about drug effects on the microstructure of eating.
Pen and paper VAS measures of appetite (hunger, full-
ness, desire to eat, prospective consumption, satisfaction,
thirst and nausea) fluctuations throughout the day will
also be collected allowing analysis of drug effects on
satiety between meals. Taken together these data fully
characterise drug effects on appetite and eating behav-
iour. All intake, appetite and eating behaviour measure-
ments are taken at baseline, 7 days, 14 days, 14 weeks
and 26 weeks.
Indirect calorimetry
Energy expenditure, resting metabolic rate (RMR) and
RQ will be measured by indirect calorimetry data using
a ventilated hood system and derived using the Weir
equation.14 15 Measurements will be started after 5 min
and performed for a 20 min period prior to the test
meal and at 60, 120, 180 and 240 min postprandially.
The first 5 min of each measurement will be discarded
to allow for complete acclimatisation to the hood and
the recumbent position, so that participants will have
reclined for 10 min prior to any measurements being
recorded for analysis. Urinary nitrogen excretion will be
estimated by collecting all urine produced over the
eight-hour period of observation in the laboratory and
multiplying by a factor of 3 to approximate 24-hour
urinary nitrogen excretion. Urine glucose excretion will
also be measured over the same time period.
Imaging visits (visits 0, 2, 4, 8, 12)
Participants will be asked to attend the MRI unit on a
separate day to the test meal; baseline measurements
will be taken after screening and no more than 1 week
Table 2 Assessments and procedures during screening and study visits
Procedure
D
−21 to −2
D
0
D
5–6
D
7
D
12–13
D
14
W
6
W
10
W
13–14
W
14
W
18
W
22
W
25–26
W
26
Visit 0 1 2 3 4 5 6 7 8 9 10 11 12 13
Informed consent X
Physical examination X X X
Fasting visit X X X X X X
Bloods X X X
Pregnancy test X
Urinalysis X X
Height X
Weight X X X X X
BP, pulse X X X X
ECG X X
Glucometer provision and training X
Drug dispensing X X X X X
Drug administration X X X X X X X X X X
AE reporting X X X X X X X X X
Con-med check X X X X X X X X X X
Compliance check X X X X X X X X X
8 hour urine X X X X X
Telephone reminder X X X X X
Test meal X X X X X
TFEQ X X
fMRI X X X X X
MR/MRS X X X
AE, adverse event; BP, blood pressure; D, day; fMRI, functional MRI; MRS, magnetic resonance spectroscopy; TFEQ, three factor eating
quotient; W, week.
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before baseline test meal; other visits should take place
within 1 week before or after the relevant test meal (for
the week 24 visit this should be in the week preceding
the final study visit/meal).
Neural response to food cues (fMRI)
BOLD response to food images is assessed using a 3.0
Tesla Siemens Trio scanner (Siemens, Erlangen,
Germany). Participants view sets of images of high
calorie (hedonic) foods, low calorie (non-hedonic)
foods and non-food control objects, in a fasted state,
then again 1 and 3 hours after consuming a fixed load
breakfast. This is conducted to understand drug effects
on the central mechanisms underpinning eating behav-
iour. The brain areas of interest are defined as hypothal-
amus, lingular gyrus, posterior insula, anterior cingulate
gyrus, pre-central gyrus, posterior cingulate gyrus,
middle frontal gyrus and lateral orbitofrontal cortex.
Activation in areas of the brain involved in regulatory/
homeostatic control of appetite (insula/hypothalamus)
can be assessed on and off drug, in different states of
satiety and over time. Furthermore, this design allows for
observation of drug-related changes to reward neurocir-
cuitry in response to hedonic versus non-hedonic food
images. Neural pathways associated with reward-related
behaviour and motivation to consume interact with
homeostatic brain regions to control appetite and
energy balance, thus fMRI data can provide a neuro-
physiological correlate of drug effects on food reward
and homeostatic hunger.16 These measurements will be
made at baseline, and at 5 or 6 days, 12 or 13 days and
at 13–14 and 25–26 weeks (before the test meal evalua-
tions). MR images will be imported into Statistical
Parametric Mapping software (SPM12) for processing,
followed by statistical analysis to test for significant
regional BOLD response change. Following the fMRI
session in the fasted state trial participants will be pro-
vided with breakfast.
Body composition
Participants will undergo MR whole body scanning in a
1.5 T Siemens Symphony scanner (Siemens Medical
Solutions, Erlangen, Germany) at a single site, the
University of Liverpool Magnetic Resonance and Image
Analysis Research Centre, as previously described.
Liver fat by MRS and body fat volume by MRI (visit 0, 8,
12)
These measurements will be made at baseline, and at 14
and 26 weeks. Proton magnetic resonance spectroscopy
of the liver will be performed as previously described.11
Three voxels of interest will be identified in the liver
standard sites avoiding ducts and vasculature. In liver,
voxel placement in post-treatment studies will be guided
by reference to the pretreatment images. 1H MR spectra
will be quantified using the AMARES algorithm in the
software package jMRUI V.3.0. Intrahepatocellular lipid
content (IHCL) is expressed as percentage of CH2 lipid
signal amplitude relative to water signal amplitude after
correcting for T1 and T2.17 Fat quantification by 1H-MRS
has been validated against gold standard biochemical
measurements.18 The mean interexamination coefficient
of variation (CoV) for using this protocol is 7% (range 4–
12%), and the mean intraexamination CoV is 6%.17
Changes in visceral and subcutaneous fat volume by MRI
Abdominal subcutaneous adipose tissue (abdominal
SAT) and abdominal visceral adipose tissue (abdominal
VAT) will be calculated from whole body axial
T1-weighted fast spin echo scans (axial scans, 10 mm
slice thickness followed by a 10-mm gap using the inte-
gral body coil). All images will be anonymised and
blinded to time point, but not to subject (to facilitate
matching anatomical landmarks), and analysed by
Vardis (Vardis Group, London, UK) using SliceOMatic
(Tomovision, Montreal, Canada), as described previ-
ously:11 the mean CoV for this methodology is total
body fat, 1–2%; total subcutaneous fat, 3–4%; abdominal
subcutaneous fat, 1–3%; visceral fat, 6–8%.
Monitoring/dispensing visits (6, 7, 10, 11)
These visits will involve a brief consultation with the
study team to review glycaemic control (self-monitored
capillary blood glucose), adverse effects and compliance
(tablet count) and to collect supply of medication.
Pharmacovigilance
All adverse events will be reported and assignment of the
severity/grading (mild, moderate, severe, life-
threatening, death) made by the investigator responsible
for the care of the participant. The assignment of causal-
ity will be made by the investigator. All non-serious
adverse events (SAEs), whether expected or not, will be
recorded and updated at each study visit. All new SAEs
will be reported from the point of consent until 70 days
after discontinuation of the investigational medical
product (IMP); this includes those thought to be asso-
ciated with protocol-specified procedures. Investigators
will report SAEs, serious adverse reactions (SARs) and
sudden unexpected adverse reactions (SUSARs) to
LCTU within 24 hours of the local site becoming aware
of the event. LCTU will notify the Medicines and
Healthcare products Regulatory Agency (MHRA) and
main REC of all SUSARs occurring during the study: fatal
and life-threatening SUSARs within 7 days of notification
and non-life-threatening SUSARs within 15 days. All
adverse events will be followed until satisfactory reso-
lution or until the investigator responsible for the care of
the participant deems the event to be chronic or the
patient to be stable.
Trial monitoring and oversight committees
The study will be overseen by the Trial Steering
Committee (TSC). Day-to-day running of the trial will be
coordinated by the Trial Management Group (TMG)
supported by the LCTU, which will consist of the
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protocol committee members and the trial manager.
The responsibilities will include
A. Report to the TSC.
B. Maintain the Trial Master File.
C. Confirm all approvals are in place before release of
the trial treatment and the start of the trial at a site.
D. Provide training about the trial.
E. Provide study materials.
F. Data management centre.
G. Give collaborators regular information about the pro-
gress of the study.
H. Respond to any questions (eg, from collaborators)
about the trial.
I. Ensure data security and quality and observe data
protection laws.
J. Safety reporting.
K. Ensure trial is conducted in accordance with the ICH
GCP.
L. Statistical analysis.
M. Publication of trial results.
The role of the TSC is to provide overall supervision
of the trial. In particular, the TSC will concentrate on
the progress of the trial, adherence to the protocol,
patient safety and consideration of new information.
The TSC must be in agreement with the final protocol
and, throughout the trial, will take responsibility for:
A. Major decisions such as need to change the protocol
for any reason.
B. Monitoring and supervising the progress of the trial.
C. Reviewing relevant information from other sources.
D. Considering recommendations from the DMC.
E. Informing and advising the TMG on all aspects of
the trial.
The TSC will include experienced diabetes patients,
other medical experts and clinical trialists. Meetings will
be held at regular intervals determined by need, but no
less than once a year. The ultimate decision for the con-
tinuation of the trial lies with the TSC.
Outline of analysis
General approach
Continuous baseline characteristics will be summarised
using mean, SD, median and interquartile range.
Categorical variables will be summarised as frequencies
and percentages. All point estimates will be considered
to be statistically significant at the 5% level (two-sided)
and will be presented with accompanying 95% CIs. No
adjustment will be made for multiple comparisons.
Analysis
Primary and secondary outcome variables will be ana-
lysed using a covariance pattern linear mixed model (or
other mixed model); the treatment effect will be
adjusted for sex as a main effect (since it is a stratifica-
tion factor), prerandomisation baseline values and the
effect of period where relevant. An interaction test will
be used to assess the treatment by period interaction
(which may be indicative of a carry-over effect) and
results interpreted cautiously if this is found to be signifi-
cant at the 10% significance level. Although a common
analysis strategy under such circumstances is to under-
take a between-group treatment comparison using only
the results from period 1, we follow the advice of
Senn19 20 in avoiding doing so because of the inflation
in the type I error rate when conducting such a com-
parison conditional on the interaction test being statistic-
ally significant.
Rate of eating and satiety quotient
Cumulative intake data will initially be analysed for
between-condition differences at each time point (every
minute). These Dunnett’s t-tests will be corrected conser-
vatively for multiple comparisons (p<0.001). A standard
technique for the examination of individual cumulative
intake curves, relying on the visual judgement of deceler-
ation by raters blinded to condition, will be used.21 This
assessment will be quantified by raters calculating the
coefficient of the start and end of individual cumulative
intake curves to confirm their initial assessment. Curves
whose coefficients are not lower at the end of the meal
than at the start are classified as non-decelerating. The
between-participant difference will be tested using a
within participants χ2 test (McNemar test).
fMRI analysis
MR images will be imported into the Statistical
Parametric Mapping software (SPM12) for processing,
followed by statistical analysis to test for significant
regional BOLD response changes.
Safety analysis
Information relating to adverse events (including events
relating to hypoglycaemia and urinary and genital tract
infections) will be tabulated and summarised descrip-
tively. Continuous laboratory values will be summarised
as described above.
DISSEMINATION
This study is being conducted in accordance with Good
Clinical Practice (GCP), as defined by the International
Conference on Harmonisation (ICH) and in compli-
ance with the European Union Directive 2001/20/EC
transposed into UK law as statutory instrument 2004 No
1031: Medicines for Human Use (Clinical Trials)
Regulations 2004 and all subsequent amendments and
the United States Code of Federal Regulations, Title 21,
Part 50 (21CFR50). The trial protocol has received the
favourable opinion of the NRES North West—Liverpool
Central Research Ethics Committee (14/NW/0340;
protocol number UoL000987).
An appropriate patient information sheet and consent
forms describing in detail the trial interventions/pro-
ducts, trial procedures and risks were approved by the
ethical committee (IEC), and the patient will be asked
to read and review the document. The investigator will
8 Rajeev SP, et al. BMJ Open 2017;7:e013539. doi:10.1136/bmjopen-2016-013539
Open Access
M
edical Library. Protected by copyright.
 o
n
 August 7, 2020 at Assistant Librarian St Jam
es`s Hospital
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-013539 on 27 January 2017. Downloaded from 
then explain the study to the patient and answer any
questions that may arise. A contact point where further
information about the trial may be obtained will be pro-
vided. After being given adequate time to consider the
information, the patient will be asked to sign the
informed consent document. A copy of the informed
consent document will be given to the patient for their
records and a copy placed in the medical records, with
the original retained in the investigator site file. The
patient may withdraw from the trial at any time by revok-
ing the informed consent. The rights and welfare of the
patients will be protected by emphasising to them that
the quality of medical care will not be adversely affected
if they decline to participate in this study.
REGULATORY APPROVAL
This trial has been registered with the MHRA and has
been granted a Clinical Trial Authorisation (CTA). The
CTA reference is its EudraCT Number: 2013-004264-60.
PUBLICATION
The results will be analysed together and published as
soon as possible. The Uniform Requirements for
Manuscripts Submitted to Biomedical Journals (http://
www.icmje.org/) will be respected. The ISRCTN allo-
cated to this trial would be attached to any publications
resulting from this trial.
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